WuXi TIDES: difference between revisions
Diff·revision 15 → 16·08:00, 6 Jan 2025
Difference between revision 15 and revision 16 of WuXi TIDES. 3 lines changed; the page grew by 950 bytes.
| Revision 15 — 11:23, 18 Dec 2024 EndotoxinEd (talk) add the lead time for catalogue lines, as reported 7,597 bytes +144 | Revision 16 — 08:00, 6 Jan 2025 Chromatokid (talk) move a stray full stop inside the reference 8,547 bytes +950 | ||
|---|---|---|---|
| 52 | Reports on WXT material submitted to PeptidePedia between 2024 and 2026 cover the incretin analogues most heavily, with a smaller number on research peptides. Where a report and the accompanying certificate can be compared, reported [[Area percent purity|area percent]] figures have generally agreed within a few tenths of a percent.{{r|reports}} | 52 | Reports on WXT material submitted to PeptidePedia between 2024 and 2026 cover the incretin analogues most heavily, with a smaller number on research peptides. Where a report and the accompanying certificate can be compared, reported [[Area percent purity|area percent]] figures have generally agreed within a few tenths of a percent.{{r|reports}} |
| 53 | 53 | ||
| + | 54 | What agreement between a certificate and an independent report establishes should be stated precisely: two measurements of the same sample agreed, which rules out a certificate written for that sample without measurement. It does not establish that the sample represents the lot, because none of these reports arose from a [[Blind sampling|blind sampling]] procedure with a documented [[Chain of custody|chain of custody]] — a limitation of the evidence available to this wiki rather than of any organisation covered by it.{{r|reports}} Purchasers wanting a figure convertible to a mass should request the [[Peptide content|peptide content]] and water determinations alongside the purity, which the organisation supplies on request against a named lot.{{r|usp1503}} | |
| + | 55 | ||
| 54 | == References == | 56 | == References == |
| 55 | {{reflist}} | 57 | {{reflist}} |
| ⋮ | ⋮ | ||
| 58 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | 60 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> |
| 59 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 61 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 62 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 60 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 63 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 61 | 64 |